AR062840A1 - Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) - Google Patents
Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)Info
- Publication number
- AR062840A1 AR062840A1 ARP070104063A ARP070104063A AR062840A1 AR 062840 A1 AR062840 A1 AR 062840A1 AR P070104063 A ARP070104063 A AR P070104063A AR P070104063 A ARP070104063 A AR P070104063A AR 062840 A1 AR062840 A1 AR 062840A1
- Authority
- AR
- Argentina
- Prior art keywords
- her2
- trastuzumab
- pertuzumab
- receiver
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Método para el tratamiento de un paciente que padece un cáncer HER2 positivo, que no responde a la monoterapia con los anticuerpos anti -HER2 trastuzumab o pertuzumab, con una combinacion de trastuzumab y pertuzumab. La invencion también proporciona los correspondientes productos elaborados. La utilizacion del trastuzumab para la elaboracion de un medicamento para la prevencion o reduccion de la metástasis en un paciente que padece de cáncer HER2 positivo, que no responde a una monoterapia con tastuzumab ni a una monoterapia con pertuzumab, que se caracteriza por una coadministracion de trastuzumab y pertuzumab de forma simultánea o secuencial. Un producto de elaboracion que se caracteriza porque comprende un contenedor, una composicion dentro de este contenedor que comprende trastuzumab y pertuzumab, y un prospecto con instrucciones para el usuario de la composicion para la coadministracion de trastuzumab y pertuzumab a un paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019317 | 2006-09-15 | ||
| EP07006616 | 2007-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062840A1 true AR062840A1 (es) | 2008-12-10 |
Family
ID=38608749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104063A AR062840A1 (es) | 2006-09-15 | 2007-09-13 | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080102069A1 (es) |
| AR (1) | AR062840A1 (es) |
| CL (1) | CL2007002667A1 (es) |
| PE (1) | PE20080663A1 (es) |
| TW (1) | TW200820987A (es) |
| WO (1) | WO2008031531A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2407556C (en) | 2000-05-19 | 2011-06-21 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| KR20120068807A (ko) * | 2004-07-22 | 2012-06-27 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0518104B8 (pt) | 2005-01-21 | 2021-05-25 | Genentech Inc | artigo industrializado e uso de anticorpo her2 |
| UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US8012914B2 (en) | 2006-10-27 | 2011-09-06 | Halliburton Energy Services, Inc. | Ortho ester breakers for viscoelastic surfactant gels and associated methods |
| CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| US8883149B2 (en) | 2008-09-15 | 2014-11-11 | Yeda Research And Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| CN102215688A (zh) * | 2008-10-21 | 2011-10-12 | 安龙制药公司 | 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗 |
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| JP2013500253A (ja) * | 2009-07-22 | 2013-01-07 | エンゾン ファーマシューティカルズ，インコーポレーテッド | ７−エチル−１０−ヒドロキシカンプトテシンのマルチアーム型ポリマー性複合体と組み合わせたｈｅｒ２受容体拮抗薬を用いるｈｅｒ２陽性がんの治療方法 |
| US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| MX347981B (es) * | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| CA2832389A1 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| CA2832387A1 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
| WO2012156975A1 (en) | 2011-05-16 | 2012-11-22 | Yeda Research And Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| FR2976294B1 (fr) * | 2011-06-10 | 2018-02-16 | Universite De Nice Sophia Antipolis | Methode de prediction de la reponse a un traitement avec un agent bloquant her2 |
| EP4234033A3 (en) | 2011-10-14 | 2023-09-20 | F. Hoffmann-La Roche AG | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| EP2793941A1 (en) | 2011-12-23 | 2014-10-29 | F.Hoffmann-La Roche Ag | Articles of manufacture and methods for co-administration of antibodies |
| US9527913B2 (en) | 2012-05-02 | 2016-12-27 | Symphogen A/S | Humanized pan-HER antibody compositions |
| EP2986643A2 (en) | 2013-04-16 | 2016-02-24 | F. Hoffmann-La Roche AG | Pertuzumab variants and evaluation thereof |
| KR101453462B1 (ko) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| CN106456784A (zh) * | 2014-04-16 | 2017-02-22 | 拜康有限公司 | 包含摩尔过量的山梨醇的稳定蛋白质制剂 |
| MX2016014007A (es) | 2014-04-25 | 2017-01-11 | Genentech Inc | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. |
| US20180250420A1 (en) * | 2014-11-13 | 2018-09-06 | The Curators Of The University Of Missouri | Multiple human antibody-nanoparticle conjugates and methods of formation |
| CA2968258A1 (en) * | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| PT3302551T (pt) | 2015-05-30 | 2024-08-21 | H Hoffnabb La Roche Ag | Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente |
| TW201709929A (zh) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | 治療癌症的聯合療法 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| KR101796277B1 (ko) | 2016-04-12 | 2017-11-13 | 앱클론(주) | 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체 |
| EP3534948A1 (en) | 2016-11-04 | 2019-09-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
| SI3570884T1 (sl) * | 2017-01-17 | 2021-02-26 | Genentech, Inc. | Subkutane formulacije protiteles HER2 |
| KR102417583B1 (ko) | 2017-03-02 | 2022-07-07 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| JP7438496B2 (ja) * | 2019-06-11 | 2024-02-27 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用 |
| EP4182688A1 (en) * | 2020-07-14 | 2023-05-24 | F. Hoffmann-La Roche AG | Assays for fixed dose combinations |
| CA3242047A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
| MX2024006978A (es) | 2021-12-07 | 2024-07-19 | Io Therapeutics Inc | Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784045B2 (en) * | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
-
2007
- 2007-09-07 WO PCT/EP2007/007802 patent/WO2008031531A1/en active Application Filing
- 2007-09-12 TW TW096134095A patent/TW200820987A/zh unknown
- 2007-09-13 PE PE2007001235A patent/PE20080663A1/es not_active Application Discontinuation
- 2007-09-13 AR ARP070104063A patent/AR062840A1/es unknown
- 2007-09-13 US US11/854,584 patent/US20080102069A1/en not_active Abandoned
- 2007-09-13 CL CL2007002667A patent/CL2007002667A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20080663A1 (es) | 2008-05-17 |
| US20080102069A1 (en) | 2008-05-01 |
| TW200820987A (en) | 2008-05-16 |
| CL2007002667A1 (es) | 2008-01-25 |
| WO2008031531A1 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
| MX2010005099A (es) | Usos de anticuerpos anti-cd40. | |
| ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| JOP20190260A1 (ar) | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها | |
| JP2015214582A5 (es) | ||
| HK1243943A1 (zh) | 使用抗IL-1α抗體治療癌症 | |
| MY150756A (en) | Tumor theraphy with an anti-vegf antibody | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| MX348579B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
| UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
| MY152864A (en) | Treatment of metastatic breast cancer | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| AU2011332810A8 (en) | Anti-IL-6 antibodies for the treatment of oral mucositis | |
| AR050036A1 (es) | Anticuerpos anti - igf- ir y sus usos | |
| UA89350C2 (uk) | Гуманізоване антитіло, що зв'язує людський cd20 | |
| IN2014KN00871A (es) | ||
| ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
| WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |